Storia in 1 fonti

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results - Axsome Therapeutics (NASDAQ:

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

Raccontata da

benzinga.com

Timeline cronologica

martedì 11 agosto 2026·benzinga.com
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results - Axsome Therapeutics (NASDAQ:
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.